Medicines labeled for the same conditions

Alternatives to eribulin

12 other medicines are given the same way (intravenous) and in the same FDA class as eribulin or labeled mainly for the same use (breast cancer); 2 are in its class, microtubule inhibitors: docetaxel and paclitaxel; the others include 4 her2/neu receptor antagonists, 1 nucleoside metabolic inhibitor and 1 estrogen receptor antagonist (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as eribulin?

Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Boxed warning	Shortage
Eribulinmicrotubule inhibitor	this medicine	14 labelers	n/a	No	No current entry
Docetaxelmicrotubule inhibitor · same class	Breast cancer	14 labelers	n/a	Yes	A presentation being discontinued
Paclitaxelmicrotubule inhibitor · same class	Breast cancer	20 labelers	n/a	Yes	No current entry
Gemcitabinenucleoside metabolic inhibitor	Breast cancer	10 labelers	n/a	No	No current entry
Trastuzumabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Margetuximabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab emtansine	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab-strfher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Fulvestrantestrogen receptor antagonist	Breast cancer	1 labeler	n/a	No	A presentation being discontinued
Ixabepilone	Breast cancer	none listed	n/a	Yes	No current entry
Pertuzumabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Sacituzumab govitecan	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab deruxtecan	Breast cancer	none listed	n/a	Yes	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Eribulin: the full record: label, generics, price, shortages, recalls